ASCO Genitourinary Cancers Symposium | Conference

Sumanta K. Pal, MD, FASCO, on CONTACT-03 Trial and Investigating Targeted Therapy, Immunotherapy for Patients with RCC
March 12, 2021

Pal detailed the plan for the CONTACT-03 study and what the research team hopes to see with the data.

Michael Szarek, PhD, on Research Areas of Focus for Tivozanib in RCC
March 11, 2021

The expert from SUNY Downstate Medical Center spoke about areas of research for renal cell carcinoma which he believes deserve further attention.

Sumanta K. Pal, MD, FASCO, on Moving Forward with Cabozantinib as Treatment for Patients with RCC
March 10, 2021

Pal discussed the emergence of cabozantinib as a treatment option for patients with renal cell carcinoma and touched on future research around the drug.

Robert J. Motzer, MD, on Research Areas of Focus in Renal Cell Carcinoma
March 09, 2021

The medical oncologist at Memorial Sloan Kettering Cancer Center discussed areas of research in renal cell carcinoma that he thinks should be further explored.

Sumanta K. Pal, MD, FASCO, on Tolerability of Lenvatinib and Everolimus to Treat Patients With RCC
March 08, 2021

Pal detailed the phase 2 trial of lenvatinib at 2 starting doses plus everolimus to treat patients with renal cell carcinoma.

Robert J. Motzer, MD, on the Possible Impact of a Phase 3 Trial for Advanced ccRCC
March 07, 2021

The medical oncologist at Memorial Sloan Kettering Cancer Center explained how this trial of MK-6482 plus lenvatinib versus cabozantinib in patients with advanced clear cell renal cell carcinoma could possibly improve the standard of care in this setting.

Robert J. Motzer, MD, on a Phase 3 Trial Evaluating MK-6482 Plus Lenvatinib Versus Cabozantinib for Advanced ccRCC
March 04, 2021

The medical oncologist at Memorial Sloan Kettering Cancer Center highlighted what clinicians treating patients with advanced ccRCC should understand about this trial in progress.

Michael Szarek, PhD, on Treatment Advances With Tivozanib for RCC Going Forward
March 03, 2021

The expert from SUNY Downstate Medical Center highlighted areas in which he believes treatment for renal cell carcinoma will advance.

Michael Szarek, PhD, on the Next Steps for Tivozanib in Patients with Advanced RCC
March 01, 2021

An analysis revealed that as a third- or fourth-line treatment for advanced renal cell carcinoma, tivozanib significantly increased Q-TWiST compared with sorafenib, primarily through an increase in TWiST.

Robert J. Motzer, MD, on Outcomes of the Phase 3 CheckMate 9ER Trial in Advanced RCC
February 28, 2021

The medical oncologist at Memorial Sloan Kettering Cancer Center discussed the significance of the phase 3 CheckMate 9ER study results.